Levacetylleucine - IntraBio
Alternative Names: AQNEURSA; IB-1001 - IntraBio; N-Acetyl-L-Leucine - IntraBioLatest Information Update: 02 Sep 2026
At a glance
- Originator University of Munich; University of Oxford
- Developer IntraBio
- Class Acetamides; Amino acids; Esters; Neuroprotectants; Pentanoic acids; Small molecules; Vestibular disorder therapies
- Mechanism of Action Calcium channel modulators
-
Orphan Drug Status
Yes - Tay-Sachs disease; Niemann-Pick disease type C; Ataxia telangiectasia
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Niemann-Pick disease type C
- Preregistration Ataxia telangiectasia
- Phase III Migraine; Spinocerebellar ataxias; Type 2 episodic ataxia
- Phase II Sandhoff disease; Tay-Sachs disease
Most Recent Events
- 17 Aug 2026 Phase-III clinical trials in Migraine (In children, In adolescents, In adults, In the elderly) in Germany, USA, United Kingdom, Switzerland, Italy, Austria (PO) (NCT07221292)
- 17 Aug 2026 Phase-III clinical trials in Spinocerebellar ataxias (In children, In adolescents, In adults, In the elderly) in United Kingdom, Switzerland, Italy, Germany, Austria, USA (PO) (NCT07221292)
- 17 Aug 2026 Phase-III clinical trials in Type-2 episodic ataxia (In children, In adolescents, In adults, In the elderly) in USA, United Kingdom, Switzerland, Italy, Germany, Austria (PO) (NCT07221292)